LENZ Therapeutics (LENZ) has submitted a Marketing Authorization Application to the United Kingdoms Medicines and Healthcare products Regulatory Agency for the review and approval of VIZZ 1.44%, the first aceclidine-based eye drop for the treatment of presbyopia in adults. The company noted that the submission of the MAA in the United Kingdom represents the sixth ex-U.S. regulatory submission for VIZZ. It received FDA approval in July 2025.
The MAA submission is supported by positive data from three randomized, double-masked, controlled Phase 3 studies conducted in the United States.
In pre-market trading on NasdaqGS, LENZ shares are down 2.8 percent to $9.89.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.